Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Milrinone infusion, Placebo infusion.
- Who it may be relevant to
- Registry conditions: Post-ligation Cardiac Syndrome. Basic parameters: up to 3 months · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the lungs and tissues. The main questions it aims to answer are: 1. to determine if milrinone decreases the risk of death or PLCS within 7 days of the procedure, compared to standard treatment; and 2. to determine the effects of milrinone on two-year survival and neurodevelopmental outcome.
Detailed description
Researchers will compare milrinone to a placebo saline solution to see if it helps the heart work better by supplying oxygen to the lungs and tissues.
After randomization the following will happen in both the control and treatment groups:
* Infant will start receiving either a low dose (0.33 μg/kg/min) of milrinone in the treatment group, OR saline solution in the control group through an intravenous (IV) line. The study drug will be started within 2 hours of the PDA closure procedure. * For the first 2 to 4 hours, the study team will monitor very closely to see if there are any major side effects from the study drug. * If the infant continues to have high blood pressure, which places an added stress on the heart, the dose will go up to 0.66 μg/kg/min. One more increase will be allowed to 0.75 μg/kg/min. The study drug will then stay at this dose. No more changes will happen to the dose. If there are side effects, then the study drug will be stopped and will not be started again. * The study drug will be stopped after 24 hours if the infant only required the lowest drug and remains well. If the required higher doses of milrinone, it will take longer to wean them off the medication. Some infants may receive milrinone for 3-5 days. If the infant's heart starts to work better by using less oxygen from the breathing machine (ventilator), the study drug may be stopped before 3 days. * Information will be collected from the infant's medical record including demographic information, gestational age, blood pressures, heart rates, respiratory rates, information about his or her breathing, medications, details of medical treatment for PDA, medical procedures including echocardiograms (ultrasound of the baby's heart), details of PDA closure (by surgery or transcatheter closure), head ultrasounds, and diagnoses. The investigators will also be collecting information from the maternal medical record including ultrasounds that may be relevant to the infant's course. * Right after the study drug is stopped (which could be 5 days or less) the doctor may decide to give the infant the drug milrinone. This is a decision that will be made by the infant's doctor. * After the infant goes home from the hospital, they will be scheduled for follow-up exams in the clinic. The follow-up visit will be done when the infant is about 2 years old. The visit will take about two hours to do. During the follow-up visit the investigators will test the infant's movement, behavior, and development. The investigators will also check the infant to make sure they do not have high blood pressure or any evidence of kidney disease.
Interventions
- Drug Milrinone infusion
An intravenous (iv) infusion of milrinone will be administered at an initial dose of 0.33 mcg/kg/min and accompanied by an iv bolus of 10 mL/kg of 0.9% NaCl (administered over 60 minutes). - Drug Placebo infusion
An iv infusion of placebo (0.9% saline) of equivalent volume will be administered. The infusion will be accompanied by an iv bolus of 10 mL/kg of 0.9% NaCl (administered over 60 minutes) to ensure blinding is maintained.
Primary outcome measures
- Post-ligation cardiac syndrome (PLCS) or death within 7 days of PDA closure [Time frame: Onset within 48 hours but may last up to 7 days]
Secondary outcome measures (12)
- Systemic hypotension [Time frame: Onset within 48 hours but may last up to 7 days]
- Systemic hypertension [Time frame: Onset within 48 hours but may last up to 7 days]
- Oxygenation failure [Time frame: Onset within 48 hours but may last up to 7 days]
- Ventilation failure [Time frame: Within 72 hours of PDA closure]
- Vasopressor score [Time frame: Within 7 days of PDA closure]
- Use of open-label milrinone or systemic vasodilator after cessation of study drug administration [Time frame: After study drug cessation and within 7 days of PDA closure]
- Time to successful extubation [Time frame: 36 weeks postmenstrual age]
- Post-intervention Moderate-severe bronchopulmonary dysplasia at 36 weeks' gestation [Time frame: 36 weeks postmenstrual age]
- Post-intervention Chronic Pulmonary hypertension [Time frame: 36 weeks postmenstrual age]
- Post-intervention Periventricular Leukomalacia (PVL) [Time frame: 36 weeks postmenstrual age]
- Post-intervention Necrotizing Enterocolitis [Time frame: 36 weeks postmenstrual age]
- Post-intervention Retinopathy of Prematurity (ROP) ≥ stage 3 (according to the international classification) [Time frame: 36 weeks postmenstrual age]
Eligibility criteria
Inclusion criteria
- Gestational age at birth ≤27 weeks (and 6 days) and postnatal age < 3 months at intervention
- Invasive or non-invasive positive pressure respiratory support (does not include low flow nasal cannula)
- Hemodynamically significant PDA with minimum transductal diameter ≥1.0 mm within 2 days of intervention
- Decision by clinical team to proceed with PDA closure via surgical ligation or percutaneous cardiac catheterization based on clinical and echocardiography features of hemodynamic significance.
Exclusion criteria
- Any major congenital malformation
- Congenital heart disease (except small (≤1mm) muscular ventricular septal defects, or small/moderate (<3mm) atrial septal defect)
- Acute renal failure defined by urine output < 0.5 mL/kg/hour OR rise of serum creatinine by 0.3 mg/dL within 48 hours OR rise of serum creatinine more than 40% above baseline serum creatinine within prior 72 hours.
- Systemic administration of vasodilator/inodilator agents
- Prior history of arrhythmia
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Prevention
Study locations
United States · 19 centers
- University of Alabama - Birmingham — Birmingham
- Children's Hospital of Orange County — Orange
- Stanford University — Palo Alto
- Sharp Mary Birch Hospital for Women & Newborns — San Diego
- Emory University — Atlanta
- Northwestern Lurie Children's Hospital of Chicago — Chicago
- University of Iowa — Iowa City
- Boston Children's Hospital — Boston
- … and 11 more centers
Publications
- McNamara PJ, Chock VY, Rahde-Bischoff A, Gabrio J, Johnson KJ, Harmon HM, Montoya-Williams D, Colaizy TT, Katheria AC, Ines F, Sorrells K, Battersby C, Levy PT, Rysavy MA, Bhombal S, Laughon MM, Carper B, Hintz SR, Das A, Bell EF. Evaluating the efficacy and safety of milrinone for prevention of post-patent ductus arteriosus closure syndrome (the MIDAS trial) in extremely preterm infants: a multic PMID 40858367
Identifiers
NCT: NCT06679855 · NICHD-NRN-0066 · U24HL166580